This article is more than 5 years old. Information may no longer be current.

Akorn acquires Betimol from Santen

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Akorn has acquired the new drug application for and all rights to Betimol from Santen, according to a press release.

Akorn intends to begin distribution of Betimol (timolol ophthalmic solution 0.25% and 0.5%) in the first quarter of this year.

The transaction is expected to add $8 million to $9 million in revenues and $0.03 to $0.04 of adjusted net income per diluted share for Akorn in 2014, the release said.

In November, Akorn acquired from Merck the U.S. rights to three branded ophthalmic products: AzaSite (azithromycin ophthalmic solution), Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution) and Cosopt PF (dorzolamide hydrochloride 2%-timolol maleate 0.5% ophthalmic solution).